Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 3220 results found since Jan 2013.
siRNA as a potential therapy for COVID-19
Curr Drug Deliv. 2021 Aug 5. doi: 10.2174/1567201818666210805145320. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) is a highly contagious virus causing COVID-19 disease that severely impacted the world health, education, and economy systems in 2020. The numbers of infection cases and reported deaths are still increasing with no specific treatment identified yet to halt this pandemic. Currently, several proposed treatments are under preclinical and clinical investigations now, alongside the race to vaccinate to as much individuals as possible. The genome of SARS-CoV2 share similar...
Source: Current Drug Delivery - August 6, 2021 Category: Drugs & Pharmacology Authors: Ahmad Aljaberi Eman M Migdadi Khalid M Abu Khadra Mahmoud Abu Samak Iman A Basheti Nizar Al-Zoubi Source Type: research
Hyaluronic acid-modified redox-sensitive hybrid nanocomplex loading with siRNA for non-small-cell lung carcinoma therapy
Drug Deliv. 2022 Dec;29(1):574-587. doi: 10.1080/10717544.2022.2032874.ABSTRACTA novel hyaluronic acid (HA)-modified hybrid nanocomplex HA-SeSe-COOH/siR-93C@PAMAM, which could efficiently deliver siRNA into tumor cells via a redox-mediated intracellular disassembly, was constructed for enhanced antitumor efficacy. Thereinto, siR-93C (siRNA) and positive PAMAM were firstly mixed into the electrostatic nano-intermediate, and then diselenide bond (-SeSe-)-modified HA was coved to shield excessive positive charges. This hybrid nanocomplex displayed uniform dynamic sizes, high stability, controlled zeta potential and narrow PDI...
Source: Drug Delivery - February 14, 2022 Category: Drugs & Pharmacology Authors: Daoyuan Chen Peng Zhang Minghui Li Congcong Li Xiaoyan Lu Yiying Sun Kaoxiang Sun Source Type: research
Biomimetic cell membrane-coated nanocarriers for targeted siRNA delivery in cancer therapy
Drug Discov Today. 2023 Jan 31:103514. doi: 10.1016/j.drudis.2023.103514. Online ahead of print.ABSTRACTSmall interfering RNA (siRNA) therapeutics for cancer are a focus of increasing research interest. However, the major obstacle to their clinical application is the targeted delivery of siRNA to cancer cells at desirable levels. Cell membrane-coated nanocarriers have the advantage of combining the properties of both cell membranes and nanoparticles (NPs). In this review, we highlight the most common RNAi therapeutics and the extracellular and intracellular barriers to siRNA delivery. Moreover, we discuss clinical applicat...
Source: Drug Discovery Today - February 3, 2023 Category: Drugs & Pharmacology Authors: Xin Huang Haoyu Guo Lutong Wang Zhicai Zhang Weiyue Zhang Source Type: research
siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight
AAPS PharmSciTech. 2023 Aug 11;24(6):170. doi: 10.1208/s12249-023-02629-1.ABSTRACTSince the ground-breaking discovery of RNA interference (RNAi), scientists have made significant progress in the field of small interfering RNA (siRNA) treatments. Due to severe barriers to the therapeutic application of siRNA, nanoparticle technologies for siRNA delivery have been designed. For pathological circumstances such as viral infection, toxic RNA abnormalities, malignancies, and hereditary diseases, siRNAs are potential therapeutic agents. However, systemic administration of siRNAs in vivo remains a substantial issue due to a lack o...
Source: AAPS PharmSciTech - August 11, 2023 Category: Drugs & Pharmacology Authors: Krittika Chatterjee Sagheerah Lakdawala Sheikh Shahnawaz Quadir Dinesh Puri Dinesh Kumar Mishra Garima Joshi Sanjay Sharma Deepak Choudhary Source Type: research
